Vitamin D OPG/RANKL and Inflammation with Alendronate Treatment in HIV-infected Patients with Reduced Bone Mineral Density

摘要

ObjectivesTo determine the effect of alendronate (ALN) on inflammatory markers and osteoprotegerin (OPG)/receptor activator of nuclear factor-kappaB ligand (RANKL), and to explore the associations of baseline systemic inflammation and vitamin D status on the bone mineral density (BMD) response to ALN.